83015-26-3

Basic information

• Product Name: (R)-Tomoxetine
• Synonyms: n-methyl-3-(2-methylphenoxy)benzenepropanamine;(r)-tomoxetine;Tomoxetine;TomoxetineHcl;N-Methyl--(2-methylphenoxy)benzenepropanamine;N-Methyl-3-(2-methylphenoxy)-3-phenylpropylamine;(R)-N-Methyl-3-phenyl-3-(2-methylphenoxy)-1-propanamine;Methyl[(R)-3-phenyl-3-(2-methylphenoxy)propyl]amine
• CAS NO: 83015-26-3
• Molecular Formula: C17H21NO
• Molecular Weight: 255.355
• EINECS: 1533716-785-6
• Product Categories: Inhibitors;Pharmacetes & Fine Chemicalsuticals
• Mol File: 83015-26-3.mol
• Article Data: 27

Chemical Properties

• Boiling Point: 389 °C at 760 mmHg
• Flash Point: 164.1 °C
• Appearance: /
• Density: 1.023 g/cm³
• Vapor Pressure: 2.95E-06mmHg at 25°C
• Refractive Index: 1.552
• PKA: 10.15±0.10(Predicted)
• CAS DataBase Reference: (R)-Tomoxetine(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-Tomoxetine(83015-26-3)
• EPA Substance Registry System: (R)-Tomoxetine(83015-26-3)

Safety Data

• Safety Statements: 22-24/25
• Hazardous Substances Data: 83015-26-3(Hazardous Substances Data)

Usage

Uses

(R)-Tomoxetine is a compound active at novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases.

Definition

(R)-Tomoxetine is a secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.

InChI:InChI=1/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1

Upstream product

• 5764-85-2 Ethyl 3-hydroxy-3-phenylpropanoate 
• 67-56-1 methanol 
• 435293-68-8 N-Desmethylatomoxetine 
• 60960-88-5 N-methyl-3-phenylprop-2-en-1-amine 
• 95-49-8 2-methylchlorobenzene 
• 115290-81-8 (R)-N-methyl-3-phenyl-3-hydroxypropylamine 
• 115290-79-4 (R)-3-(2-methylphenoxy)-3-phenylprop-1-yl methanesulfonate 
• 74-89-5 methylamine 
• 114446-47-8 -(-)-1-chloro-3-phenyl-3-(2-methylphenoxy)propane 
• 118856-08-9 butyric acid 2-ethoxycarbonyl-1-phenyl-ethyl ester 
• 838841-85-3 (3S) ethyl β-butyryloxy-β-phenyl propionate 
• 132203-26-0 (S)-3-hydroxy-3-phenylpropanenitrile 
• 105314-53-2 (S)-N-methyl-3-(2-methylphenoxy)-3-phenyl-1-propanamine 
• 1537223-06-5 (R)-3-phenyl-3-(2-methylphenoxy)propanal 

Downstream Products

• 82248-59-7 atomoxetine hydrochloride 
• 851086-84-5 S-rivastigmine-atomoxetine 
• 1027094-45-6 (R)-atomoxetine oxalate 
• 134619-78-6 (-)-N-tert-butoxycarbonyl-N-methyl-3-phenyl-3-(2-methylphenoxy)propanamine 

Relevant articles and documents

Preparation method of cefamoxetine hydrochloride

The invention discloses a preparation method of tamoxidectin hydrochloride, belongs to the technical field of drug synthesis, and uses 3 - chlorine -1 - phenylpropanone as a raw material to undergo a reduction reaction. The synthesis route has the advantages of few reaction steps, mild reaction conditions,3 - simple 2 - operation, cheap -3 - and easily available raw materials, and low production cost 3 - and -1 - R-chloro - N - phenylpropanone is used as a raw material.

Preparation method of atomoxetine hydrochloride

The invention belongs to the technical field of medicines, and particularly relates to a preparation method of atomoxetine hydrochloride serving as a medicine for treating attention deficit hyperactivity. According to the invention, commercially available (E)-N-methyl-3-phenyl-2-propylene-1-amine is adopted as a starting material, and addition, substitution and salification are carried out so as to prepare atomoxetine hydrochloride. The preparation method provided by the invention is simple in preparation process, simple and convenient to operate, relatively high in yield and suitable for industrial production, and can provide sufficient bulk drugs for research and development of medicines.

Preparation method of atomoxetine

The invention belongs to the technical field of medicines, and particularly relates to a preparation method of atomoxetine hydrochloride serving as a medicine for treating attention deficit hyperactivity. Commercially available 3-(methylamino)-1-phenylacetone is adopted as a starting material, and undergoes asymmetric reduction, substitution and other reactions to prepare the atomoxetine. The invention mainly aims to prepare the atomoxetine by an asymmetric synthesis method and expand a preparation method of the atomoxetine hydrochloride.